Compare Vertex Pharmaceuticals Incorporated (VRTX) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs State Street Technology Select Sector SPDR ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $525.84 (market cap $134.25B), while State Street Technology Select Sector SPDR ETF trades at $189.19. The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, State Street Technology Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals.
| VRTX | XLK | |
|---|---|---|
Market Cap | $134.25B | — |
Sector | Health | Sector/Thematic |
52-Week High | $529.65 | $198.21 |
52-Week Low | $376.62 | $127.49 |
Enterprise Value | $128.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
XLK trades at $189.38, up 1.64% with strong technical momentum as moving averages signal bullish conditions. The Technology Select Sector SPDR Fund shows institutional interest with record sector ETF inflows of $25 billion in July 2026 (ETF Trends, 2026-08-10). Recent earnings strength from holdings like Microsoft supports the fund's performance, though RSI levels suggest potential near-term overbought conditions.
Outlook remains positive given sector earnings growth and AI-driven momentum, but risks include concentration in mega-cap stocks and valuation concerns. The fund's heavy reliance on top holdings creates sensitivity to individual company performance, requiring careful monitoring of diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
